Levetiracetam Solution
Product Images NDC 72205-037

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72205-037). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle-label (Bottle Label)

Bottle-label (Bottle Label)
Levetiracetam is a medication that comes in oral form and is typically used in accordance with the directions provided on the package insert. This drug is distributed by Novadoz Pharmaceuticals LLC and is available in 100 mg/mL strength. Proper storage is crucial and it should be kept at a temperature range of 20°C to 25°C (68°F to 77°F), with brief excursions to 15°C to 30°C (59°F to 86°F) allowed as per USP Controlled Room Temperature guidelines. This medication should be kept out of the reach of children and dispensed by a pharmacist in a light-resistant, tight container with a child-resistant closure. Manufacturing details indicate that it is produced by MSN Pharmaceuticals Inc.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This text is a comparison between the effects of placebo and two different doses of a medication called Levetiracetam in two groups of different sizes (95 and 97 in the placebo group, and 101 in the Levetiracetam 3000mg/day group).*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This is the result of a clinical trial that compared the response of patients taking a placebo (104 individuals) versus those taking a 3000 mg/day dose of Levetiracetam (180 individuals). The percentages indicate the proportion of patients that experienced the desired effect, but the nature of this effect is not available.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This text appears to be showing the percentage of patients in a study who were given a placebo (44.6%) and those who were given levetiracetam (19.6%). The number of patients for each group is also provided (97 for placebo and 101 for levetiracetam). It is likely that this information is being used to compare the effectiveness of the placebo and levetiracetam in treating a particular condition, but without more context it is impossible to say for certain.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.